Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy

Abstract Gene therapy uses modern molecular biology methods to repair disease‐causing genes. As a burgeoning therapeutic, it has been widely applied for cancer therapy. Since 1989, there have been numerous clinical gene therapy cases worldwide. However, a few are successful. The main challenge of clinical gene therapy is the lack of efficient and safe vectors. Although viral vectors show high transfection efficiency, their application is still limited by immune rejection and packaging capacity. Therefore, the development of non‐viral vectors is overwhelming. Nanoplatform‐based non‐viral vectors become a hotspot in gene therapy. The reasons are mainly as follows. 1) Non‐viral vectors can be engineered to be uptaken by specific types of cells or tissues, providing effective targeting capability. 2) Non‐viral vectors can protect goods that need to be delivered from degradation. 3) Nanoparticles can transport large‐sized cargo such as CRISPR/Cas9 plasmids and nucleoprotein complexes. 4) Nanoparticles are highly biosafe, and they are not mutagenic in themselves compared to viral vectors. 5) Nanoparticles are easy to scale preparation, which is conducive to clinical conversion and application. Here, an overview of the categories of nanoplatform‐based non‐viral gene vectors, the limitations on their development, and their applications in cancer therapy.